Amneal Pharmaceuticals, Inc (AMRX) 2025 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, and welcome to the Amneal Pharmaceuticals fourth quarter and full year 2025 earnings call. I'll now hand the call over to Amneal's Head of Investor Relations, Tony Dimeo. Go ahead, please, sir.

    早安,歡迎參加Amneal Pharmaceuticals 2025年第四季及全年財報電話會議。現在我將把電話交給Amneal的投資人關係主管Tony Dimeo。請便,先生。

  • Anthony Dimeo - Head of Investor Relations

    Anthony Dimeo - Head of Investor Relations

  • Good morning, and thank you for joining the Amneal Pharmaceuticals fourth quarter 2025 earnings call. Today, we issued a press release reporting Q4 results. The earnings press release and presentation are available at amneal.com.

    早安,感謝各位參加Amneal Pharmaceuticals 2025年第四季財報電話會議。今天,我們發布了第四季度業績新聞稿。財報新聞稿和簡報可在amn​​eal.com上取得。

  • Certain statements made on this call regarding matters that are not historical facts, including, but not limited to, management's outlook or predictions are forward-looking statements that are based solely on information that is now available to us. Please see the section entitled cautionary statements on forward-looking statements for factors that may impact future performance.

    本次電話會議中就非歷史事實事項所作的某些陳述,包括但不限於管理階層的展望或預測,均為前瞻性陳述,僅基於我們目前掌握的資訊。請參閱題為「前瞻性陳述的警示性聲明」的部分,以了解可能影響未來績效的因素。

  • We also discuss non-GAAP measures. Information and use of these measures and the reconciliations to GAAP are in the earnings release and presentation.

    我們也討論了非GAAP指標。有關這些措施的資訊和使用以及與 GAAP 的調節情況,請參閱盈利報告和簡報。

  • On the call today are Chirag and Chintu Patel, Co-Founders and Co-CEOs, Tasos Konidaris, CFO; our commercial leaders; Andy Boyer for Affordable Medicines; Joe Renda for Specialty; and Jason Daly, Chief Legal Officer.

    今天參加電話會議的有:聯合創始人兼聯合首席執行官 Chirag 和 Chintu Patel,首席財務官 Tasos Konidaris;我們的商業領導人;平價藥品負責人 Andy Boyer;專科藥品負責人 Joe Renda;以及首席法律官 Jason Daly。

  • I will now hand the call over to Chirag.

    現在我將把電話交給奇拉格。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, Tony, and good morning, everyone. 2025 was a defining year of excellent execution and portfolio expansion at Amneal.

    謝謝托尼,大家早安。 2025年是Amneal業績卓越、產品組合拓展的關鍵一年。

  • As a diversified biopharmaceutical company across specialty complex products, injectables and biosimilars, we're building category leadership positions in large and growing markets. In 2025, revenue grew 8%, adjusted EBITDA increased 10%, adjusted EPS rose 43%. 2025 marks our sixth consecutive year of growth in our industry, that consistency of growth stands out.

    作為一家業務多元化的生物製藥公司,我們的產品涵蓋特種複雜產品、注射和生物相似藥,我們正在大型且不斷成長的市場中建立品類領導地位。2025年,公司營收成長8%,調整後EBITDA成長10%,調整後每股收益成長43%。 2025年是我們連續第六年在產業內成長,這種持續成長的勢頭尤其突出。

  • What's most exciting is not only what we have achieved so far, which we are truly proud of but the even greater opportunity that lies ahead.

    最令人興奮的不僅是我們迄今為止所取得的成就(我們為此感到非常自豪),更是未來更大的機會。

  • We entered 2026 with a strong foundation and exciting strategic growth opportunities, whether we are advancing the standard of care with innovative therapies like CREXONT or expanding access to affordable complex medicines, our mission is clear, to become America's number one affordable medicines company.

    進入 2026 年,我們擁有堅實的基礎和令人興奮的策略成長機會。無論是透過 CREXONT 等創新療法提高護理標準,還是擴大獲得價格合理的複雜藥物的機會,我們的使命都很明確,那就是成為美國排名第一的平價藥品公司。

  • Since our founding over 20 years ago, Amneal has always been driven by the deep passion and responsibility to serve the millions of patients who rely on our medicines every day and we're just getting started. Let me begin with our largest segment, Affordable Medicines.

    自 20 多年前成立以來,Amneal 一直秉持著服務數百萬每天依賴我們藥物的患者的熱忱和責任感,而我們才剛起步。讓我先從我們最大的業務板塊——平價藥品開始說起。

  • The business continues to grow year after year, driven by an expanding portfolio of complex differentiated and durable products.

    由於不斷擴大的複雜、差異化和耐用產品組合,公司業務持續逐年成長。

  • 2025 was an exceptional year for approvals and launches, particularly in complex generics and injectables. These launches are not onetime events.

    2025 年是藥品審批和上市數量異常豐收的一年,尤其是在複雜仿製藥和注射劑領域。這些發表會並非一次性活動。

  • They are multiyear value drivers. As a result, we expect meaningful acceleration in our affordable medicine segment, revenue growth in 2026 and '27. In Injectables, we are executing with a clear ambition to become a top FIVE player in the US institutional market. Over the years, we have significantly expanded our R&D and manufacturing capabilities, adding the technical capabilities required for long-term leadership.

    它們是多年價值驅動因素。因此,我們預計在 2026 年和 2027 年,我們的平價藥品業務將顯著加速成長,營收也將成長。在註射劑領域,我們的目標是成為美國機構市場前五大企業。多年來,我們大幅擴展了研發和製造能力,增加了長期保持領先所需的技術能力。

  • Our strategy focuses on providing differentiated offerings for hospitals, including ready-to-use specialty injectables. With over 40 products and a pipeline of differentiated launches, we expect this business to scale substantially over time. In biosimilars, we're building a long-term growth engine.

    我們的策略重點是為醫院提供差異化產品,包括即用型特殊注射。我們擁有 40 多種產品,並有一系列差異化產品即將上市,預計這項業務將隨著時間的推移而大幅擴展。在生物相似藥領域,我們正在建立一個長期成長引擎。

  • We began with in-licensing and creating a strong commercial platform. In December, we received approval for our denosumab biosimilars, our fourth and fifth products.

    我們首先透過引進授權和建立強大的商業平台起步。12 月,我們的第四款和第五款產品——地諾單抗生物相似藥——獲得了批准。

  • With biosimilar Xolair in the review, we remain on track to have six biosimilars in the US market by 2027. Strategically, our goal remains to be vertically integrated in biosimilars across development, manufacturing and commercialization, which we believe is essential for long-term success.

    如果生物相似藥 Xolair 進入審查範圍,我們仍有望在 2027 年前在美國市場推出六種生物相似藥。從策略來看,我們的目標仍然是在生物相似藥的研發、生產和商業化方面實現垂直整合,我們認為這對於長期成功至關重要。

  • From a macro perspective, the opportunity is remarkable. Over the next decade, about 234 millions of biologic cells will lose exclusivity, more than double the prior 10 years. And only about 10% of those products have biosimilars in development.

    從宏觀角度來看,這是一個絕佳的機會。未來十年,約有 2.34 億個生物細胞將失去獨佔權,是前 10 年的兩倍多。其中只有約 10% 的產品正在研發生物類似藥。

  • This creates a significant long-term opportunity to dramatically expand patient access and drive very meaningful growth for our company. Next, on GLP-1, our collaboration with Pfizer is progressing well and both teams are working together.

    這為我們公司創造了一個重要的長期機會,可以大幅擴大患者的就醫途徑,並推動公司實現意義深遠的成長。接下來,關於 GLP-1,我們與輝瑞的合作進展順利,兩個團隊正在共同努力。

  • We are here to assist Pfizer in a meaningful way. This initiative builds on what we do best: develop, manufacture and commercialize complex medicines at scale and position us to play a meaningful long-term role in one of the largest and fastest-growing therapeutic categories in health care.

    我們來這裡是為了以有意義的方式幫助輝瑞公司。這項計畫建立在我們最擅長的領域:大規模開發、生產和銷售複雜的藥物,並使我們能夠在醫療保健領域規模最大、成長最快的治療類別之一中發揮有意義的長期作用。

  • Now let's turn to the Specialty segment. We're very pleased with the uptake of CREXONT. At the end of 2025, our 23,000 patients were on therapy, reflecting over 3% market share one year post launch.

    現在我們來看專業領域部分。我們對 CREXONT 的市場接受度非常滿意。截至 2025 年底,我們的 23,000 名患者正在接受治療,反映出產品上市一年後,我們的市佔率超過 3%。

  • For context, RYTARY reached roughly 42,000 patients and 6% market share 10 years after launch. In December, Interim Phase IV data reinforced that what physicians and patients are already seeing, CREXONT delivers more good on time than other therapies.

    作為參考,RYTARY 在上市 10 年後,擁有約 42,000 名患者和 6% 的市場份額。12 月公佈的 IV 期中期數據進一步證實了醫生和患者已經看到的現象:CREXONT 比其他療法更及時地帶來療效。

  • We remain confident in peak US sales of $300 million to $500 million for CREXONT which we believe is setting a new standard of care for Parkinson's patient. In the fourth quarter, we launched Brekiya, a first and only auto-injector for severe migraine and cluster headache patients.

    我們仍然對 CREXONT 在美國的銷售高峰充滿信心,預計達到 3 億至 5 億美元,我們相信 CREXONT 將為帕金森氏症患者樹立新的護理標準。第四季度,我們推出了 Brekiya,這是第一款也是目前唯一一款用於治療嚴重偏頭痛和叢集性頭痛的自動注射器。

  • For many of these patients, the prior option was an emergency room visit. Brekiya gives them control, delivering the same hospital medication in a ready-to-use auto-injector. Brekiya is our next growth catalyst in specialty with expected peak sales of $50 million to $100 million.

    對許多這類患者來說,之前的選擇是去急診室就診。Brekiya 讓他們掌控用藥,透過即用型自動注射器輸送與醫院相同的藥物。Brekiya 是我們下一個特種產品成長催化劑,預計高峰銷售額將達到 5,000 萬美元至 1 億美元。

  • Lastly, health care continues to provide diversification and strategic advantage through government and distribution channels, health care strengthens our direct access to key end markets and provides an efficient path for new launches, including bio seamless, complex generics and specialty products.

    最後,醫療保健透過政府和分銷管道繼續提供多元化和戰略優勢,醫療保健加強了我們直接進入關鍵終端市場的管道,並為新產品的推出提供了一條高效的途徑,包括生物無縫、複雜的仿製藥和專科產品。

  • Overall, we are building a diversified biopharmaceutical company that expands access and provides new therapies for patients and delivers consistent growth for investors.

    總而言之,我們正在打造一家多元化的生物製藥公司,擴大患者獲得治療的機會,為患者提供新的療法,並為投資者帶來持續成長。

  • With that, I'll turn it over to Chintu.

    接下來,我將把麥克風交給欽圖。

  • Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

    Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, Chirag, and good morning. I will begin with gratitude and thank the global Amneal team for their dedication and hard work, which continue to drive our company's success.

    謝謝你,奇拉格,早安。首先,我要表達我的感激之情,感謝安耐爾全球團隊的奉獻和辛勤工作,正是他們的付出不斷推動著公司的成功。

  • The formula for strong execution remains the same: operational excellence, robust innovation and the differentiated portfolio.

    實現卓越執行的秘訣仍然不變:卓越的營運、強勁的創新和差異化的產品組合。

  • First, on operations, our global manufacturing network and leading technical capabilities remain a core strategic advantage. We continually enhance efficiency through digitization, automation, and AI, which will drive cost efficiencies.

    首先,在營運方面,我們的全球製造網路和領先的技術能力仍然是核心戰略優勢。我們不斷透過數位化、自動化和人工智慧來提高效率,這將降低成本。

  • In GLP-1s, our collaboration with Pfizer is progressing very well. Our manufacturing build-out of two new GLP-1 facilities remain on target, one for large-scale peptide production and one for advanced sterile fill-finish manufacturing designed to support all dosage forms.

    在 GLP-1 受體激動劑領域,我們與輝瑞的合作進展非常順利。我們新建的兩座 GLP-1 設施的生產建設仍在按計劃進行,一座用於大規模肽類生產,另一座用於先進的無菌灌裝包裝生產,旨在支持所有劑型。

  • We are well positioned to participate meaningfully in the long-term GLP-1 market with the scalable and flexible manufacturing platform. In Affordable Medicine, we look to launch 20 to 30 new products each year. Importantly, it is not just the number of launches, but the value and complexity of these products that matter.

    憑藉可擴展且靈活的生產平台,我們完全有能力在長期的 GLP-1 市場中發揮重要作用。在平價藥品領域,我們計劃每年推出 20 至 30 種新產品。重要的是,重要的不僅是產品發布的數量,還有這些產品的價值和複雜性。

  • In that regard, in 2025 was an exceptionally strong year. For years, we have strategically prioritized the development of complex generics, including injectables, ophthalmics, inhalation products and other advanced drug device combinations.

    就此而言,2025 年是表現格外強勁的一年。多年來,我們一直將複雜仿製藥的開發作為策略重點,包括注射劑、眼科用藥、吸入產品和其他先進的藥物器材組合。

  • As a result, we are now in the midst of one of the most concentrated and impactful waves of high-value affordable medicine launches in Amneal's history. During the fourth quarter, we meaningfully expanded our portfolio with a series of important late 2025 approvals and launches across multiple areas.

    因此,我們現在正處於 Amneal 史上最集中、影響最大的高價值平價藥品上市浪潮之一。第四季度,我們在多個領域獲得了一系列重要的批准,並將於 2025 年底推出,從而顯著擴展了我們的產品組合。

  • Highlights included risperidone extended-release, our first long-acting injectable, sodium oxybate, Bimatoprost and cyclosporin in ophthalmic, the first generic for iohexol and multiple other injectables for hospitals, including several epinephrine products.

    亮點包括利培酮緩釋劑(我們的第一款長效注射劑)、羥丁酸鈉、比馬前列素和環孢素眼科用藥(碘海醇的首個仿製藥)以及多種其他醫院用注射劑,包括幾種腎上腺素產品。

  • Notably, we also announced approval and now launching our first two innovation products: beclomethasone dipropionate and albuterol sulfate. This reflects a decade of hard work by the team and marks our new entry into inhalation, which is new growth platform starting this year.

    值得一提的是,我們也宣布批准並推出了我們的首批兩款創新產品:二丙酸倍氯米松和硫酸沙丁胺醇。這體現了團隊十年的辛勤努力,也標誌著我們正式進軍吸入領域,這是一個從今年開始的新增長平台。

  • With this level of activity, we are reaching an inflection point in complex innovation. Today, we have 59 ANDA spending with 64% classified as complex products and 52 more products in development with 94% complex. We look to file 10 to 15 key complex programs in 2026, including several more injectables and inhalation programs.

    按照目前的活躍程度,我們正處於複雜創新領域的轉捩點。目前,我們有 59 項 ANDA 支出,其中 64% 被歸類為複雜產品;另有 52 項產品正在開發中,其中 94% 為複雜產品。我們計劃在 2026 年提交 10 至 15 個關鍵的複雜項目,其中包括幾個注射和吸入劑項目。

  • This complex portfolio evolution positions us very well for sustainable growth. In biosimilars, we continue to build our business deliberately over time.

    這種複雜的投資組合演變使我們處於可持續成長的有利地位。在生物相似藥領域,我們將繼續穩步發展,逐步壯大我們的業務。

  • Our next major milestone is biosimilar Xolair, which represents our sixth potential biosimilar and our largest opportunity to date. Xolair was one of the first blockbuster allergy biologics, and we expect to be among the first biosimilars in this over $4 billion US market next year.

    我們的下一個重大里程碑是生物相似藥 Xolair,這是我們第六個潛在的生物相似藥,也是我們迄今為止最大的機會。Xolair是第一批重磅過敏生物製劑之一,我們預計明年將成為這個價值超過40億美元的美國市場上的首批生物相似藥之一。

  • We are very proud of the progress we have made in building a biosimilar business. As Chirag noted, we see a very significant opportunity ahead with the upcoming wave of biologics LOEs.

    我們為在生物相似藥業務發展方面取得的進展感到非常自豪。正如 Chirag 指出的那樣,我們看到即將到來的生物製劑 LOE 浪潮帶來了非常重要的機會。

  • Success in this space will require vertical integration from cell line development and R&D to manufacturing and commercial capabilities. That is what will be needed to be a long-term leader in biosimilar.

    在這個領域取得成功需要從細胞系開發和研發到生產製造和商業化能力的垂直整合。這是成為生物相似藥領域長期領導者所必需的條件。

  • In Specialty, CREXONT continues to perform exceptionally well and believe it has the potential to become the standard of care for all people living with Parkinson's disease.

    在專科領域,CREXONT 繼續表現出色,我們相信它有潛力成為所有帕​​金森氏症患者的標準治療方案。

  • For decades, the foundation of treatment has been immediate release carbidopa/levodopa, a therapy that dates back to 1970s. IR CD-LD is limited by fluctuating symptom control, frequent dosing and significant off time as the disease progresses.

    幾十年來,治療的基礎一直是速釋卡比多巴/左旋多巴,這種療法可以追溯到 20 世紀 70 年代。IR CD-LD 的限制在於症狀控制不穩定、需要頻繁給藥,並且隨著病情進展會出現明顯的停藥期。

  • CREXONT represents a meaningful advancement in therapy designed to address these long-lasting limitations by delivering more consistent system control with fewer daily doses. In 2024, we initiated a phase IV real-world study of approximately 225 patients converting them from RYTARY, IR CD-LD and IR CD-LD with COMT inhibitors to CREXONT.

    CREXONT 代表了治療領域的重大進步,旨在透過減少每日劑量,提供更穩定的系統控制,從而解決這些長期存在的限制。2024 年,我們啟動了一項 IV 期真實世界研究,研究對象為約 225 名患者,他們將 RYTARY、IR CD-LD 和 IR CD-LD 與 COMT 抑制劑聯合治療轉換為 CREXONT 治療。

  • In December, we shared the first interim results from this open-label study which demonstrated clear and clinically meaningful differentiation, patients treated with CREXONT experienced substantially more good on time less of time and longer intervals of continuous good on time.

    去年 12 月,我們分享了這項開放標籤研究的首個中期結果,結果顯示,接受 CREXONT 治療的患者在臨床上表現出明顯且有意義的差異,其「良好狀態」持續時間明顯更長,持續「良好狀態」的持續時間明顯更短。

  • Importantly, patients converted from IR to CREXONT showed over three hours more good on time per day, a result that is highly meaningful for Parkinson's patients. We look to generate further evidence to demonstrate CREXONT's effectiveness and expect to share more data for 2026 and 2027.

    重要的是,從 IR 轉用 CREXONT 的患者每天的有效用藥時間增加了三個多小時,這對帕金森氏症患者來說意義重大。我們希望獲得更多證據來證明 CREXONT 的有效性,並期待分享 2026 年和 2027 年的更多數據。

  • In addition, internationally, we have filed the products in a number of key countries, including India, Canada and in Europe.

    此外,在國際上,我們已在包括印度、加拿大和歐洲在內的多個主要國家提交了產品申請。

  • Beyond CREXONT, we plan to expand our specialty portfolio over time with products in areas like CNS and others, where differentiated delivery, real-world performance and patient convenience matter. Brekiya auto-injector is a clear example, combining a proven therapy with differentiated drug delivery system that improves how patients receive care.

    除了 CREXONT 之外,我們計劃隨著時間的推移,在中樞神經系統等領域擴展我們的專業產品組合,在這些領域,差異化的給藥方式、實際性能和患者便利性至關重要。Brekiya 自動注射器就是一個明顯的例子,它將成熟的療法與差異化的藥物傳遞系統結合,改善了患者接受治療的方式。

  • Specialty represents a multiproduct growth engine for Amneal, and we'll share more on our pipeline as it evolves. In summary, we are executing well, driving operational excellence advancing innovation and expanding a differentiated portfolio across affordable medicines, specialty and biosimilars. The progress we made in Q4 reinforces our confidence in the path ahead.

    特種化學品是安耐爾多元化產品成長的引擎,我們將隨著產品線的進展分享更多資訊。總而言之,我們執行良好,推動卓越運營,推動創新,並擴大在平價藥品、專科藥品和生物相似藥方面的差異化產品組合。我們在第四季度取得的進展增強了我們對未來道路的信心。

  • With that, I will turn it over to Tasos.

    這樣,我就把任務交給塔索斯了。

  • Anastasios Konidaris - Chief Financial Officer, Executive Vice President

    Anastasios Konidaris - Chief Financial Officer, Executive Vice President

  • Thank you, Chintu, and good morning, everyone. The fourth quarter completed another terrific year for Amneal with strong top and bottom line growth as Q4 revenues grew 11%, adjusted EBITDA grew 13% and adjusted EPS grew 75%.

    謝謝你,Chintu,大家早安。第四季為 Amneal 又一個輝煌的年份畫上了圓滿的句號,營收和利潤均實現了強勁增長,第四季度營收增長 11%,調整後 EBITDA 增長 13%,調整後每股收益增長 75%。

  • Our consistent performance reflects our strategic choices, relevancy of our broad portfolio, prudent capital allocation and strong execution. In addition to strong top and bottom line growth, we also delivered strong full year operating cash flow of $340 million, reduced net leverage to 3.5times and our successful refinancing extended maturities to 2032 and substantially reduced interest costs.

    我們持續穩定的績效反映了我們的策略選擇、廣泛投資組合的相關性、審慎的資本配置和強而有力的執行。除了強勁的營收和利潤成長外,我們還實現了全年強勁的營運現金流 3.4 億美元,將淨槓桿率降低至 3.5 倍,並且我們成功的再融資將到期日延長至 2032 年,並大幅降低了利息成本。

  • So all in all, an excellent finish to the year. Over the next few minutes, I'll cover in more detail on our fourth quarter and full year 2025 results and move on to our 2026 guidance.

    總而言之,這一年以完美的結束。接下來幾分鐘,我將更詳細地介紹我們 2025 年第四季和全年的業績,並展望我們 2026 年的業績指引。

  • Starting with the fourth quarter. Total company revenues grew 11% to a record $814 million. First, our affordable medicines segment was essentially flat to $437 million, reflecting the timing of key products and new launches.

    從第四節開始。公司總營收成長11%,達到創紀錄的8.14億美元。首先,我們的平價藥品業務基本上持平,達到 4.37 億美元,這反映了關鍵產品和新產品上市的時間表。

  • Second, Specialty revenues were very strong again in Q4 up 38% year-over-year to $167 million due to strong demand across our key brands such as CREXONT, RYTARY, UNITHROID and some small initial sales of our newest branded product, Brekiya auto-injector for cluster headaches.

    其次,由於 CREXONT、RYTARY、UNITHROID 等主要品牌的強勁需求,以及我們最新品牌產品 Brekiya 叢集性頭痛自動注射器的一些小規模初期銷售,第四季度特種藥品收入再次非常強勁,同比增長 38%,達到 1.67 億美元。

  • Third, Health care revenues grew 24% to $211 million driven by strong growth in the government channel. Our Q4 revenues continued to benefit by approximately $50 million associated with one significant new product lines which accounted for approximately $100 million in new revenue for the full year 2025.

    第三,醫療保健收入成長 24% 至 2.11 億美元,主要得益於政府管道的強勁成長。我們的第四季收入繼續受益於一條重要的新產品線,該產品線帶來了約 5,000 萬美元的收入,預計到 2025 年全年將帶來約 1 億美元的新收入。

  • Fourth quarter adjusted EBITDA of $175 million grew 13%, driven by top line growth and limited operating expense growth.

    第四季調整後 EBITDA 為 1.75 億美元,成長 13%,主要得益於營收成長和營運費用成長有限。

  • Q4 earnings per share of $0.21 grew 75% due to adjusted EBITDA growth and lower interest expense due to our favorable refinancing earlier in 2025. Let me now shift to our full year 2025 performance where we exceeded all our financial guidance metrics.

    第四季每股收益為 0.21 美元,成長 75%,這得益於調整後的 EBITDA 成長以及由於我們在 2025 年初進行的有利再融資而導致的利息支出減少。現在讓我來談談我們 2025 年全年的業績,我們超額完成了所有財務預期指標。

  • Total company revenue of $3 billion increased 8% driven by growth across all of our business segments as Affordable Medicines grew 4%,

    公司總收入達30億美元,成長8%,這主要得益於所有業務部門的成長,其中平價藥品業務成長4%。

  • Specialty grew 19% and Health care grew 12%. We're also very pleased by the growth of our adjusted gross margin, which expanded by 50 basis points to approximately 43%. It's worth noting that Health care's 2025 adjusted gross margin increased in excess of 400 basis points due to our concerted efforts to prioritize profitability.

    專業領域成長了 19%,醫療保健領域成長了 12%。我們對調整後毛利率的成長也感到非常滿意,毛利率成長了 50 個基點,達到約 43%。值得注意的是,由於我們齊心協力優先考慮獲利能力,醫療保健業務 2025 年調整後的毛利率增長超過 400 個基點。

  • On the bottom line, full year 2025 adjusted EBITDA grew 10% to $688 million, and adjusted EPS grew 43% to $0.83. In addition to our strong financial performance in 2025, we feel great about the actions we have taken to strengthen our balance sheet.

    整體而言,2025年全年調整後EBITDA成長10%至6.88億美元,調整後每股盈餘成長43%至0.83美元。除了2025年強勁的財務表現外,我們對加強資產負債表所採取的措施也感到非常滿意。

  • First, we have reduced net leverage from 7.4times in 2019 to 3.9times at the end of 2024 and finally, to 3.5x at the end of 2025.

    首先,我們將淨槓桿率從 2019 年的 7.4 倍降低到 2024 年底的 3.9 倍,最終降低到 2025 年底的 3.5 倍。

  • Second, we fully refinanced our debt last summer. And in January of this year, we repriced our term loan B to further lower interest rate expense. As a result, our weighted average cost of debt is down from 10% in 2024 to about 6.8% in 2026, and maturities have been extended out to 2032.

    第二,我們去年夏天完成了債務的全面再融資。今年一月,我們對 B 類定期貸款進行了重新定價,以進一步降低利息支出。因此,我們的加權平均債務成本從 2024 年的 10% 降至 2026 年的約 6.8%,到期日也延長至 2032 年。

  • Accordingly, interest expense in 2025 was $217 million compared to $256 million in 2024 and as importantly, we expect a further reduction in 2026.

    因此,2025 年的利息支出為 2.17 億美元,而 2024 年為 2.56 億美元,更重要的是,我們預計 2026 年將進一步減少。

  • I'll now turn to our full year 2026 guidance, which in summary reflects another year of growth across all financial metrics.

    接下來,我將介紹我們 2026 年全年業績指引,總而言之,該指引反映了所有財務指標又一年的成長。

  • In summary, we expect top line growth between 1% and 4%, adjusted EBITDA growth between 5% and 10%, and adjusted EPS growth between 12% and 24%. Let me provide a bit more detail on each of our guidance metrics, starting with total company revenue of $3.05 billion to $3.15 billion, up 1% to 4%, as I mentioned.

    總而言之,我們預期營收成長1%至4%,調整後EBITDA成長5%至10%,調整後每股盈餘成長12%至24%。讓我更詳細地說明我們的各項績效指引指標,首先是公司總收入為 30.5 億美元至 31.5 億美元,成長 1% 至 4%,正如我之前提到的。

  • We expect the growth to be driven by our largest business segment, Affordable Medicines where we expect growth between 7% and 8%. This is an acceleration from 4% growth in 2025, but in line with our prior 3-year average.

    我們預計成長將主要由我們最大的業務部門——平價藥品部門推動,預計該部門的成長率為 7% 至 8%。這比 2025 年 4% 的成長率有所加快,但與我們之前 3 年的平均值一致。

  • Our growth expectation is rooted in the robust cadence of new product launches we received from the FDA in the last couple of months.

    我們對成長的預期源於過去幾個月我們從 FDA 獲得的強勁的新產品上市節奏。

  • As a result, we're entering 2026 with the highest number of product approvals which derisks our growth expectations. In our specialty segment, we expect 2026 revenues to be about flat to 2025.

    因此,我們在進入 2026 年時擁有最多的產品批准數量,這降低了我們成長預期的風險。在我們的專業領域,我們預計 2026 年的營收將與 2025 年基本持平。

  • This temporary pause in growth simply reflects the continued growth of CREXONT and our other brands been offset by the expected generic erosion, RYTARY. As we look forward to 2027 and beyond, we expect our specialty business to resume its strong growth trajectory as the growth of CREXONT and our multiple other branded products overcome the loss of exclusivity of RYTARY.

    這種暫時的成長停滯僅僅反映了 CREXONT 和我們其他品牌的持續成長被預期的仿製藥侵蝕所抵消,RYTARY。展望 2027 年及以後,我們預計隨著 CREXONT 和我們其他多個品牌產品的成長,我們的特種業務將恢復強勁的成長勢頭,從而彌補 RYTARY 失去獨家經營權的影響。

  • In our Health Care segment, we expect revenue between $625 million to $700 million in 2026 compared to $745 million in 2025 and $663 million in 2024.

    在我們的醫療保健業務板塊,我們預計 2026 年的營收將在 6.25 億美元至 7 億美元之間,而 2025 年為 7.45 億美元,2024 年為 6.63 億美元。

  • While the year-over-year revenues will be down in 2026 our expected profitability is flat year-over-year as we continue our successful efforts to focus on the more profitable segments of the business.

    儘管 2026 年的同比收入將會下降,但由於我們繼續成功地專注於業務中利潤更高的部分,因此預計盈利能力將與上年持平。

  • For some of the newer audience on our call, it's worth noting that it has been about six years since we acquired 65% of Health Care, and over that time, top and bottom line have increased by over 3times.

    對於我們電話會議上的一些新聽眾來說,值得注意的是,自從我們收購了醫療保健業務 65% 的股份以來已經過去了大約六年,在此期間,收入和利潤都增長了 3 倍以上。

  • We're very excited about Health Care's growth potential given the strong fundamentals of expanding population of more than 20 million veterans and federal government workers as well as the growing portfolio of new launches such as biosimilars, complex generics and specialty products.

    鑑於超過 2000 萬名退伍軍人和聯邦政府工作人員人口不斷增長,以及生物相似藥、複雜仿製藥和專科產品等新產品組合的不斷增加,我們對醫療保健行業的增長潛力感到非常興奮。

  • Overall, Health Care remains a highly strategic direct platform for Amneal, and we expect it to continue generating substantial profits and cash flow over time.

    總體而言,醫療保健仍然是 Amneal 的一個重要策略性直接平台,我們預計它將繼續隨著時間的推移產生可觀的利潤和現金流。

  • Moving down the P&L. We expect 2026 adjusted gross margins of over 44%, which reflects approximately 100 basis points of gross margin expansion driven by the continued mix shift in our business as the higher margin parts of our business are growing faster.

    向下移動損益表。我們預計 2026 年調整後毛利率將超過 44%,這反映了毛利率成長約 100 個基點,這主要得益於我們業務結構持續轉變,其中高利潤率業務部分的成長速度更快。

  • As a result, we expect 2026 adjusted EBITDA between $720 million and $760 million, up between 5% and 10%. From an EPS perspective, we expect 2026 adjusted EPS between $0.93 and $1.03, which reflects 12% to 20% earnings growth driven by strong adjusted EBITDA growth and lower interest expense. Now in terms of quarterly phasing for 2026, we expect a gradual build over the year for a couple of reasons.

    因此,我們預計 2026 年調整後 EBITDA 將在 7.2 億美元至 7.6 億美元之間,成長 5% 至 10%。從每股盈餘的角度來看,我們預計 2026 年調整後每股盈餘將在 0.93 美元至 1.03 美元之間,這反映了在強勁的調整後 EBITDA 成長和較低的利息支出推動下,獲利成長 12% 至 20%。至於 2026 年的季度分階段實施,我們預計這一年將逐步推進,原因有二。

  • First, the revenue associated with many new affordable medicines launches as well as correction will build throughout the year. And second, some launch-related investments are more front-end loaded to support key launches such as our Brekiya auto-injector.

    首先,許多價格適中的新藥上市以及糾正措施帶來的收入將在全年持續成長。其次,一些與產品發布相關的投資更集中在前期,以支援關鍵產品的發布,例如我們的 Brekiya 自動注射器。

  • Moving on to cash.

    接下來是現金部分。

  • We expect robust 2026 operating cash flow between $325 million to $375 million compared to approximately $340 million in 2025 and CapEx of approximately $110 million or 3% of revenue.

    我們預計 2026 年強勁的營運現金流將在 3.25 億美元至 3.75 億美元之間,而 2025 年約為 3.4 億美元;資本支出約為 1.1 億美元,佔營收的 3%。

  • Lastly, we're pleased to be added to the S&P SmallCap 600 Index a month ago, which reinforces the consistency of our operating and financial performance over time.

    最後,我們很高興一個月前被納入標普小型股 600 指數,這進一步證明了我們營運和財務表現的穩定性。

  • We believe this inclusion enhances our visibility with the investment community and continued expansion of our institutional investor base. In summary, we entered 2026 in our strongest position yet and with a wind in our backs.

    我們相信,此次納入將提升我們在投資界的知名度,並持續擴大我們的機構投資者基礎。總而言之,我們以迄今為止最強勁的勢頭進入了 2026 年,並且一路順風順水。

  • We expect sustained top and bottom line growth supported by our diversified portfolio and multiple growth drivers, including new branded launches such as CREXONT and Brekiya, new biosimilar launches and a very strong wave of new affordable medicines.

    我們預計,在多元化的產品組合和多種成長動力的支持下,公司營收和利潤將持續成長,這些成長動力包括新品牌產品(如 CREXONT 和 Brekiya)、新的生物相似藥以及大量價格實惠的新藥。

  • Combined with our disciplined focus on profitable growth, operating efficiencies and strong balance sheet, we see a clear path for substantial value creation.

    結合我們對獲利成長、營運效率和強勁資產負債表的嚴格關注,我們看到了創造巨大價值的清晰路徑。

  • With that, I'll turn the call back to Chirag.

    這樣,我就把電話轉回給奇拉格了。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, Tasos. Our strong 2025 results and 2026 guidance reflect the momentum across our diversified business. We remain focused on the disciplined execution of our strategy as we progress towards coming America's leading affordable medicines company. Let's now open the call for Q&A.

    謝謝你,塔索斯。我們強勁的 2025 年業績和 2026 年業績預期反映了我們多元化業務的發展勢頭。我們將繼續專注於嚴格執行我們的策略,朝著成為美國領先的平價藥品公司的目標邁進。現在進入問答環節。

  • Operator

    Operator

  • (Operator Instructions) Chris Schott, JPMorgan.

    (操作說明)克里斯‧肖特,摩根大通。

  • Chris Schott - Analyst

    Chris Schott - Analyst

  • Great, thanks so much for the questions and congrats on all the progress. Maybe just to start out on CREXONT, post the Phase IV data for the product, can you just elaborate a little bit more on the response you're seeing in the market from these results? And maybe as part of that, as we think about 2026, how should we think about either revenue or market share targets for the product? And I just have one follow-up after that.

    太好了,非常感謝你的提問,也祝賀你取得的所有進展。或許可以先談談 CREXONT,公佈一下該產品的 IV 期臨床試驗數據,您能否再詳細闡述一下根據這些結果在市場上觀察到的反響?或許,作為其中的一部分,當我們展望 2026 年時,我們應該如何看待該產品的收入或市佔率目標?之後我還有一個後續問題。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Excellent. So well, I'll start and have my brother added on to this as well. So the Phase IV, it's interim result showing 3.13 hours of good on time, which is what we've been hearing from physicians and the experience of patients. So it's a huge uptick. 80% of the IR patients are converting to CREXONT. And the Phase IV continues.

    出色的。好吧,我先開始,然後讓我弟弟也加入進來。所以,第四階段的中期結果顯示有效持續時間為 3.13 小時,這與我們從醫生那裡聽到的以及患者的體驗相符。所以這是一個巨大的成長。 80%的IR患者都轉而使用CREXONT。第四階段繼續進行。

  • Chintu will give more details on it, and we also have another study, which he will share as well. Market share, we would double it in '26, more than double the revenue. And as we march towards the first goal is to reach 100,000 patients and second goalpost would be to reach 200,000 patients, reminding you, total is 700,000 patients on CD-LD treatment. Chintu, why don't you add more on the clinical studies, please.

    Chintu會提供更多細節,我們還有另一項研究,他也會分享。市場份額,我們將在 2026 年翻倍;收入,我們將翻倍以上。我們朝著第一個目標邁進,達到 10 萬名患者,第二個目標是達到 20 萬名患者,提醒您,接受 CD-LD 治療的患者總數為 70 萬人。Chintu,請你多補充一些臨床研究的內容。

  • Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

    Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

  • Yeah, hi Yes. Chris, so we are very excited about our interim results, which we shared for 50 patients throughout '26 and early '27, we will be sharing remainder, which is the total study was about 225 patients, and the data is looking pretty promising.

    是的,你好。克里斯,我們對中期結果感到非常興奮,我們在 2026 年和 2027 年初分享了 50 名患者的研究結果,我們將分享剩餘部分,整個研究涉及約 225 名患者,數據看起來相當有希望。

  • And we have done -- as I mentioned, converting patients first time from different therapy, not on just the IR CD-LD, we have done conversion from the RYTARY, from IR with COMT inhibitor and CREXONT is clearly showing substantial benefits of good on time compared to all those therapies.

    正如我之前提到的,我們已經成功地將患者從不同的療法轉換過來,不僅僅是 IR CD-LD,我們還成功地將患者從 RYTARY、IR COMT 抑製劑和 CREXONT 轉換過來,這顯然顯示出與所有這些療法相比,在療效方面有顯著優勢。

  • So we are very excited. We have a lot more data coming, and I think that will further enhance CREXONT's position in the market, plus we are looking at another Phase IV.

    我們非常興奮。我們還有更多數據即將公佈,我認為這將進一步提升 CREXONT 在市場上的地位,此外,我們正在考慮進行另一項 IV 期臨床試驗。

  • At the right time, we will also disclose the Phase 4, which continue to generate the data. And what we are excited about is the difference is making in patient lives. And that -- we have so many testimonies from the patient and the doctors. So I think when the product is doing well, obviously, it will reflect in the sales and the revenue and uptake. So we are very pleased and a lot more coming in '26 and '27 with new data.

    時機成熟時,我們也會公佈第四階段的研究結果,該階段將繼續產生相關數據。令我們感到興奮的是,它正在為患者的生活帶來改變。而且──我們有很多來自病人和醫生的證詞。所以我覺得,當產品表現良好時,很顯然,這會反映在銷售額、收入和市場接受度上。因此我們非常高興,並且 2026 年和 2027 年還將有更多新數據公佈。

  • Chris Schott - Analyst

    Chris Schott - Analyst

  • Great. And just one maybe quick follow-up on Health Care. Can you just -- I just want to make sure I understand the 2026 guidance relative to 2025. So can you just talk a little bit more about the growth you're expecting in that kind of higher-margin government channel versus the distribution business? And just like roughly what type of gross margins we can think about -- kind of -- for that franchise for the year?

    偉大的。最後,關於醫療保健,我可能還要簡單問一個問題。您能幫我確認一下嗎?我只是想確保我理解了 2026 年相對於 2025 年的指導方針。那麼,您能否再詳細談談您對高利潤率的政府通路與分銷業務之間成長的預期?那麼,我們大概可以估算一下該特許經營權一年的毛利率是多少呢?

  • Anastasios Konidaris - Chief Financial Officer, Executive Vice President

    Anastasios Konidaris - Chief Financial Officer, Executive Vice President

  • Yes, I can take that, Chris. This is Tasos. Yes, as I mentioned before, kind of stepping back, right? This business, when we acquired 65% of Health Care, since then, we have more than tripled the revenue, gross margins and EBITDA. So it's great because we were able to leverage both the unique assets Amneal brought to the transaction as well as the inherent growth in that business.

    是的,我可以接受,克里斯。這是塔索斯。是的,正如我之前提到的,有點像退後一步,對吧?自從我們收購醫療保健業務 65% 的股份以來,我們的營收、毛利率和 EBITDA 都成長了兩倍多。所以這很棒,因為我們既能利用 Amneal 為此交易帶來的獨特資產,又能利用該業務固有的成長潛力。

  • So as we talked about, so when you look at 2025 versus 2024, right? So in 2025, the total revenue of Health Care was about $745 million and in 2024, the revenue was $663 million. So that grew about -- total, about 12%. About 50% of the revenue is between about 40% of the revenue kind of goes into the government channel, 60% of the revenue goes in the distribution channel. So when you think about this 12% growth, 2025 versus 2024, the distribution part of the business declined, okay, while the government business grew, okay?

    正如我們剛才討論的,當你比較 2025 年和 2024 年時,對吧?因此,2025 年醫療保健的總收入約為 7.45 億美元,而 2024 年的收入為 6.63 億美元。所以總共成長了大約 12%。約 50% 的收入流向政府管道,約 40% 的收入流向分銷管道。所以,當你考慮 2025 年與 2024 年相比 12% 的成長時,你會發現業務的分銷部分下降了,而政府業務卻成長了。

  • And the distribution declined, it was purposefully done because that's what we talked about it because we decided to not chase businesses with one or two gross margin. okay? So as a result of that kind of what I would say is pivoting, right?

    分銷管道的拓展減少,這是我們有意為之,因為我們之前討論過這個問題,我們決定不再追逐那些毛利率只有一兩倍的企業。明白嗎?所以,這就是我所說的轉型的結果,對吧?

  • Into the -- kind of leaning hard into the government channel, the gross margin of our Health Care business grew over 400 basis points. So the gross margin in 2025 of Health Care was $147 million compared to about $100 million in 2024.

    透過大力拓展政府管道,我們醫療保健業務的毛利率增加了 400 多個百分點。因此,2025 年醫療保健產業的毛利為 1.47 億美元,而 2024 年約為 1 億美元。

  • And the operating income in 2025 was $94 million compared to $57 million. So essentially, '25 versus '24, revenue up 12%, gross margin up 41%, operating income up 65%. So a great performance. So now as we look into 2026, there's two things that are happening. We continue to expect the distribution business to be declining.

    2025 年的營業收入為 9,400 萬美元,而 2025 年為 5,700 萬美元。所以基本上,2025 年與 2024 年相比,收入成長了 12%,毛利率成長了 41%,營業收入成長了 65%。表現非常出色。所以現在展望 2026 年,有兩件事正在發生。我們仍預期分銷業務將會下滑。

  • But because it's such a low profitability part of the business, it doesn't hurt the bottom line. The government business is going to be down slightly, not because of anything fundamental that is happening.

    但由於這是公司利潤率很低的一部分,所以不會影響公司的最終利潤。政府業務量將略有下降,但這並非由於任何根本因素造成的。

  • But in 2025, with such an extraordinary growth because we had this one generic products, essentially, generic Entresto. That essentially we're the only ones in the market. That product had $100 million worth of revenue, as I mentioned before in 2025.

    但到了 2025 年,由於我們推出了這款通用產品,本質上就是通用版的 Entresto,因此實現瞭如此驚人的成長。實際上,我們是市場上唯一的競爭者。正如我之前提到的,該產品在 2025 年的收入達到了 1 億美元。

  • In 2026, as it always happens it will have some additional competition. So that's why in 2026, revenues declining is down because of our pivot away from distribution, number one, and not having kind of that exclusivity, if you want to call that of generic Entresto impacted the government business as well.

    到了2026年,不出所料,它將面臨一些新的競爭。所以,2026 年收入下降的原因首先是因為我們轉向了分銷,其次是因為我們失去了某種獨家性(如果你想稱之為獨家性的話),通用 Entresto 也影響了政府業務。

  • So that's what's going to drive the decline and what we like to call it almost like a reset level for 2026. But the bottom line is not going to be impacted because for a couple of reasons: a, there is other more profitable parts of the business. We will be allocating resources.

    所以這就是導致下跌的原因,我們喜歡稱之為 2026 年的重置水準。但最終利潤不會受到影響,原因有二:一、公司還有其他更賺錢的業務。我們將分配資源。

  • We'll also be leaning on some of the operating expenses. So these are the dynamics that are happening in Health Care, which essentially creates this reset revenue in 2026 before we resume top line and bottom line growth in 2027 and beyond. So I know I said a lot, Chris, let me know if that was helpful.

    我們也會利用一些營運費用。所以,這就是醫療保健領域正在發生的動態,這實際上會在 2026 年造成收入重置,然後我們會在 2027 年及以後恢復營收和利潤的成長。我知道我說了很多,克里斯,請告訴我這是否有幫助。

  • Chris Schott - Analyst

    Chris Schott - Analyst

  • That was helpful. That was perfect. Thank you so much. Appreciate it.

    那很有幫助。完美。太感謝了。謝謝。

  • Operator

    Operator

  • Thank you for that question, Chris. Moving on, we now have Matt Dellatorre, Goldman Sachs.

    謝謝你的提問,克里斯。接下來,我們請到了高盛的 Matt Dellatorre。

  • Matt Dellatorre - Analyst

    Matt Dellatorre - Analyst

  • Great, good morning guys, and thanks for the question. Maybe on the Pfizer GLP-1 obesity partnership, could you just share your latest update on the status of that partnership? And then how should we think about potential outcomes?

    太好了,各位早安,謝謝你們的提問。關於輝瑞GLP-1治療肥胖症的合作,能否分享一下該合作的最新進展?那我們該如何看待可能出現的結果呢?

  • For example, what -- if they do end up buying you out, would that be a complete return of all rights and economics? Or are there other scenarios where, for instance, maybe you don't manufacture for a developed market, but you keep emerging market rights? And then if it is a complete buyout, what would be the plan for the new facilities in India and the cash you would receive? And then I had one follow-up.

    例如,如果他們最終收購了你的股份,那是否意味著所有權利和經濟利益都將完全歸還給你?或是有其他情況嗎?例如,你可能不會為已開發市場生產產品,但保留新興市場的權利?如果是完全收購,那麼印度新工廠的計畫是什麼?你們會收到多少現金?然後我還有一次後續跟進。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • So with Pfizer, our collaborations continues such as we had it with Metsera, both teams are working together. Facilities actually accelerated in manufacturing. And we -- several levels of C-level meetings have been already conducted with Pfizer. So we expect nothing much to change.

    因此,我們與輝瑞的合作將繼續下去,就像我們之前與Metsera的合作一樣,兩個團隊正在共同努力。製造設施實際上加速運轉。我們已經與輝瑞公司舉行了多場高層會議。所以我們預計不會有太大變化。

  • Right now, it's all waiting for the starting the Phase III and getting the products and the demand is global and we have built a building, such a remarkable, highly automated, fill-and-finish facility with latest and greatest equipment.

    目前,一切都在等待第三階段的啟動和產品的交付,而需求是全球性的,我們已經建造了一座卓越的、高度自動化的填充和包裝設施,配備了最新最好的設備。

  • So Pfizer is very excited about that. And also, we are making great progress on our Peptide manufacturing, which you know is in shortages with solid phase technology, and we are also introducing hybrid in the future. So our teams are working with Pfizer on those aspects as well.

    輝瑞公司對此感到非常興奮。此外,我們在勝肽的生產方面也取得了巨大進展,您也知道,目前固相技術存在短缺,我們未來也將推出混合技術。所以我們的團隊也在與輝瑞公司就這些方面展開合作。

  • And we continue to have the marketing rights for 18 countries, including India and Southeast Asia. So we're excited about the entire partnership, and there are no plans to think about right now. It's moving great.

    我們繼續擁有包括印度和東南亞在內的 18 個國家的營銷權。所以我們對整個合作關係感到興奮,目前還沒有任何計劃需要考慮。進展順利。

  • Matt Dellatorre - Analyst

    Matt Dellatorre - Analyst

  • Okay. Awesome. That's exciting. And then maybe just on business development. Could you share your latest thoughts on the strategy, areas of interest and capacity and then how you're thinking about the potential vertical integration of biosimilars? Thank you.

    好的。驚人的。真令人興奮。然後或許就專注於業務拓展了。能否分享您對該策略、關注領域和能力的最新想法,以及您如何看待生物相似藥的潛在垂直整合?謝謝。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Yes. So as we've been saying it since last couple of years, time is now to do the vertical integration. Biosimilar opportunities are awesome, regulatory is streamlined and we are very familiar with the market. So very excited that's where the capital allocation will go first. And then as I said previously, 2027 and onward, we'll be more focused on specialty assets and keep building our pipeline there.

    是的。正如我們過去幾年一直強調的那樣,現在是時候進行垂直整合了。生物相似藥的市場機會龐大,監管流程簡化,我們對市場也非常熟悉。非常激動,資金將首先投入那裡。正如我之前所說,從 2027 年起,我們將更專注於特殊資產,並繼續拓展這方面的業務。

  • And remember, the -- organically, we are very strong in our R&D pipeline. So we keep our pipeline full. More complex products, a great team in-house we have.

    記住,從自身發展來看,我們在研發方面實力非常強大。所以我們要保持供應充足。我們擁有更複雜的產品和優秀的內部團隊。

  • So we'll continue to invest in our own R&D, our own CapEx, which is strategically we've been investing and very excited about the future and next five years, going to be tremendous growth than what we have even witnessed in last five years.

    因此,我們將繼續投資於我們自己的研發和資本支出,這是我們一直以來策略性投資的方向,我們對未來和未來五年感到非常興奮,未來五年將比過去五年所見證的成長更加巨大。

  • Matt Dellatorre - Analyst

    Matt Dellatorre - Analyst

  • Great. Thank you.

    偉大的。謝謝。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you, ma'am.

    謝謝您,女士。

  • Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

    Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

  • Thank you for that.

    謝謝。

  • Operator

    Operator

  • Thank you for that question, Matt. Moving on, we now have David Amsellem from Piper Sandler. Go ahead, please. Your line is now open.

    謝謝你的提問,馬特。接下來,我們邀請了來自 Piper Sandler 的 David Amsellem。請繼續。您的線路已開通。

  • David Amsellem - Senior Research Analyst

    David Amsellem - Senior Research Analyst

  • Hey, thanks. So just a few for me. Just a few for me. I wanted to get your thoughts on the generic Omnipaque opportunity and what has been built into your '26 expectations regarding that opportunity, talk about barriers to competition, potential approval of additional strengths. And the extent to which you think that's going to be a limited competition product for the foreseeable future. So I know that's a bunch, but that's number one. And then secondly, I had a question on Xolair.

    嘿,謝謝。我只有幾個。我只有幾個。我想了解您對通用型 Omnipaque 的機會的看法,以及您在 2026 年對該機會的預期,談談競爭障礙,以及可能批准的其他劑型。你認為在可預見的未來,該產品的競爭程度會有多低?我知道這很多,但這是第一點。其次,我還有一個關於Xolair的問題。

  • Kind of similar set of questions, but I wanted to get your thoughts on the extent to which that could be a limited competition market. I believe there's only two or three others. So talk about how big of an opportunity that could be in '27 and beyond. Thank you.

    問題類似,但我想聽聽您對這在多大程度上可能是有限競爭市場的看法。我相信只有另外兩三個人了。所以,請談談這在 2027 年及以後會是多麼大的機會。謝謝。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Great. Thank you, David. On Iohexol, the supply chain is -- it's complicated. They will be entering the market. GE has the huge market share.

    偉大的。謝謝你,大衛。關於碘海醇,其供應鏈—很複雜。他們即將進入市場。通用電氣擁有巨大的市場佔有率。

  • So we'll be making inroads. The hospitals we have spoken to, they're very excited. But expect that as a ramp-up because of the difficulty in the supply chain. So over the years, as we introduce more strength, it will pick up. So great achievement from our R&D team and complexity of manufacturing, both we have achieved.

    所以我們會取得進展。我們聯絡過的醫院都非常興奮。但預計這只是一個逐步恢復的過程,因為供應鏈有困難。所以隨著時間的推移,隨著我們不斷增強實力,它就會逐漸增強。因此,我們在研發團隊取得的巨大成就以及製造流程的複雜性方面都取得了成功。

  • So excited over time on Iohexol. On Xolair, we're very excited right now with Celltrion and us in '26, large market, growing market, very well said about we expect 65% to 70% to go through the private label, which gives us immediate bump in the cells rather than ramp up over market share over one, two, three years. So exciting opportunity.

    隨著時間的推移,我對碘海醇越來越興奮。對於 Xolair,我們現在與 Celltrion 合作非常興奮,2026 年,市場巨大且不斷增長,正如之前所說,我們預計 65% 到 70% 的產品將透過自有品牌銷售,這將使我們的電池銷量立即提升,而不是在一、二、三年內逐步擴大市場份額。真是個令人興奮的機會。

  • And as you know, Amneal is well positioned to do business with these large buying groups as we have been doing business with them over 20 years great relationship, number one pipeline in the country for them, and they appreciate our high integrity, the quality standards we have.

    如您所知,Amneal 完全有能力與這些大型採購集團開展業務,因為我們與他們合作超過 20 年,建立了良好的關係,我們為他們提供了全國第一的管道,他們也欣賞我們的高誠信和品質標準。

  • So we expect tremendous partnership with these private label side of the business, which I expect about going forward would be almost 70% would go through private label which would make the biosimilar penetration very effective.

    因此,我們期待與這些自有品牌業務建立巨大的合作關係,我預計未來將有近 70% 的產品透過自有品牌銷售,這將使生物類似藥的滲透非常有效。

  • It would not have to wait for 3, 4 years to get to 30%, 40% market share. It would jump to higher market share immediately in year 1 and 20%, 30% will continue on buy and bill, which we are well positioned as well. So very excited on solar as well. Chintu, you wanted to add anything on Iohexol?

    它無需等待 3 年、4 年才能達到 30%、40% 的市場份額。第一年,市場份額將立即躍升至更高水平,20%、30%的份額將繼續透過購買和帳單支付的方式獲得,而我們在這方面也處於有利地位。我對太陽能也感到非常興奮。Chintu,你還有什麼關於碘海醇的補充嗎?

  • Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

    Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

  • Yes, David, So on Iohexol your question on additional strength. So by end of the year, we will have approval for the missing trends. So by end of the year, we'll have the entire Omnipaque, all the strength. It's a very large opportunity for us. We have been working on strengthening our supply chain and increasing our capacity.

    是的,David,關於碘海醇的加強型問題。因此,到今年年底,我們將獲得缺失趨勢的批准。所以到今年年底,我們將擁有完整的 Omnipaque,全部實力都將發揮作用。這對我們來說是一個非常大的機會。我們一直在努力加強供應鏈並提高產能。

  • So '26, we will start but '27 onwards, it would be a meaningful revenue contribution. And from a competition perspective, it is a tough product supply chain perspective, manufacturing, it's unique bottle. So all those things put together, I think we don't foresee a lot of competition and multiple strengths. So we are very excited. And by end of the year, we'll have all the strength approved.

    所以,從 2026 年開始,但從 2027 年開始,它將帶來可觀的收入貢獻。從競爭的角度來看,這是一款競爭激烈的產品,供應鏈、製造流程以及其獨特的瓶子都面臨著嚴峻的挑戰。綜上所述,我認為我們預計不會有太多競爭,而且雙方都擁有多種優勢。我們非常興奮。到年底,所有強度指標都將獲得批准。

  • David Amsellem - Senior Research Analyst

    David Amsellem - Senior Research Analyst

  • Okay, great. That's very helpful.

    好的,太好了。那很有幫助。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you, David. Moving on, we now have Leszek Sulewski from Truist Securities.

    謝謝你,大衛。接下來,我們邀請了來自 Truist Securities 的 Leszek Sulewski。

  • Leszek Sulewski - Analyst

    Leszek Sulewski - Analyst

  • Good morning. Thank you for taking my questions. First one on CREXONT. Can you quantify the persistence at perhaps month three or six versus your internal expectations and versus RYTARY? Any sort of signal around discontinuation? And how should we think about the gross to net evolving as you brought in access? And what's kind of a steady-state gross to net you're expecting at peak?

    早安.謝謝您回答我的問題。第一個在 CREXONT 上。您能否量化一下在第三個月或第六個月的持續性與您的內部預期以及 RYTARY 的預期之間的差異?停產前後有任何徵兆嗎?隨著您引入接取方式,我們該如何看待毛利與淨利之間的變化?那麼,在高峰期,您預期穩定的毛利和淨利分別是多少?

  • And then second on the DHE auto-injector, what's the early patient profile? Is it migraine versus clusters and the switches from prior DHE exposure versus naive? Thank you.

    其次,關於DHE自動注射器,早期病患概況如何?是偏頭痛還是叢集性頭痛?以及之前接觸過二氫麥角胺(DHE)和未接觸過DHE之間的差異?謝謝。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • CREXONT versus RYTARY. Obviously, CREXONT is performing much better as RYTARY, it took almost 10 years to get to 6% market share. First year, we have 3% market share, 23,000 patients on it. testimonials are amazing, and we've received letters and -- our office literally -- written letters from patient providers are -- physicians are so excited about the product as well. And now our aim is to make that first-line therapy over time so nobody -- no patient has to take the whole filament, which is giving them a lot of fluctuations every 1.5 hours, twohours.

    CREXONT 對上 RYTARY。顯然,CREXONT 的表現比 RYTARY 好得多,它花了近 10 年才達到 6% 的市場份額。第一年,我們的市佔率為3%,有23,000名患者使用。用戶評價非常棒,我們收到了來自患者的信件,而且——我們辦公室確實收到了——來自醫生的親筆信,他們對這款產品也感到非常興奮。現在我們的目標是讓這種第一線療法逐漸普及,讓任何患者都不必再使用整根導線,從而避免每隔 1.5 小時、2 小時就會出現劇烈的波動。

  • So this is clearly a seven, eight hours, a good on time every day. So amazing stories, no comparison with RYTARY. It is -- we're doubling or more than doubling market share this year, so we'll reach 6-plus percent this year, which would be above RYTARY.

    所以很明顯,每天要準時七、八個小時。故事太精彩了,跟RYTARY比起來簡直沒辦法比。沒錯——我們今年的市佔率將翻倍甚至更多,所以我們今年將達到 6% 以上,這將超過 RYTARY。

  • And we learned -- on the pricing side, we learned everything we had about 35% of patients that could not fill that prescription due to the pricing on RYTARY. We have really worked on it and have us put the pricing out there that, that number has been reduced now.

    我們從定價方面了解到,大約有 35% 的患者由於 RYTARY 的定價問題而無法獲得處方。我們已經為此付出了很多努力,並公佈了價格,現在價格已經降低了。

  • And our gross to net runs is typical in this category, about 40% to 45%. We're very excited about CREXONT. Brekiya, Joe, you want to -- it is also -- the Brekiya is for cluster headache as well as severe migraine. So we're treating two segments and only excitement is amazing. Joe Renda is here, he just came back from our national sales meeting.

    我們的毛利與淨利潤之比在這個類別中屬於典型水平,約為 40% 至 45%。我們對 CREXONT 感到非常興奮。Brekiya,Joe,你想——它也是——Brekiya 可以治療叢集性頭痛和嚴重偏頭痛。所以我們正在處理兩個部分,而只有興奮感令人驚嘆。喬·倫達來了,他剛從我們的全國銷售會議回來。

  • Would you like to shed some light on Brekiya?

    能否介紹一下 Brekiya?

  • Joe Renda - Senior Vice President, Chief Commercial Officer

    Joe Renda - Senior Vice President, Chief Commercial Officer

  • Sure. Yes. Thanks so much for the question. And yes, the response from the field team so far has been fantastic on both CREXONT and Brekiya auto-injector because what we're seeing in the market from the key KOLs has been very favorable. I would say with regards to your question about CREXONT with persistence and adherence, it continues to improve as we continue to see more and more patients on the product.

    當然。是的。非常感謝你的提問。是的,到目前為止,現場團隊對 CREXONT 和 Brekiya 自動注射器的回饋都非常棒,因為我們從市場上的關鍵意見領袖那裡看到的回饋非常積極。關於您提出的關於 CREXONT 的持續性和依從性的問題,隨著越來越多的患者使用該產品,其效果也在不斷提高。

  • And right now, it's surpassing that of RYTARY. And we continue to -- we anticipate to see that continue to go up because we're seeing patients return to therapy at a higher rate with CREXONT than they did with RYTARY.

    而現在,它已經超過了RYTARY。我們預計這一數字還會繼續上升,因為我們看到使用 CREXONT 的患者重新接受治療的比例比使用 RYTARY 的患者更高。

  • So that's been very favourable. With Brekiya auto-injector, our strategy has been to focus on the key migraine treatment centres across the United States and key KOLs and the response has been beyond our expectations so far. So we've been very pleased.

    所以這方面非常有利。對於 Brekiya 自動注射器,我們的策略是專注於美國各地的主要偏頭痛治療中心和關鍵意見領袖,到目前為止,反應超出了我們的預期。我們非常滿意。

  • We're about 90 days into the launch. And having come back now from our sales and marketing meeting -- our national meeting this week, I'm maybe more further convinced that we're going to continue to drive growth for both of those products. The team is trained and ready, and we're going to be executing this year. So excited about that.

    我們已經上線大約90天了。本週我們召開了全國銷售和行銷會議,回來後,我更加確信我們將繼續推動這兩款產品的成長。團隊已經訓練完畢,準備就緒,今年我們將全力以赴。對此我感到非常興奮。

  • Leszek Sulewski - Analyst

    Leszek Sulewski - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Thank you, Les, and checking the Q&A list now, and we are now all clear. And with that, I'll go ahead and hand it back to Chirag Patel for some final remarks. Go ahead, please.

    謝謝你,萊斯,我現在查看了問答列表,現在一切都清楚了。接下來,我將把發言權交還給奇拉格·帕特爾,請他作最後總結發言。請繼續。

  • Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

    Chirag Patel - President, Co-Chief Executive Officer, Co-Founder, Director

  • Well, thank you, everyone, for joining the call today. Have a great Friday and weekend. Thank you.

    謝謝大家今天參加電話會議。祝你週五和週末愉快!謝謝。

  • Anastasios Konidaris - Chief Financial Officer, Executive Vice President

    Anastasios Konidaris - Chief Financial Officer, Executive Vice President

  • Thanks everyone.

    謝謝大家。

  • Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

    Chintu Patel - Co-Chief Executive Officer, Co-Founder, Director

  • Okay, thanks everyone.

    好的,謝謝大家。

  • Operator

    Operator

  • Thank you, gentlemen. And this concludes today's call. Thank you all for joining. You may now disconnect your lines and have a great weekend.

    謝謝各位先生。今天的電話會議到此結束。感謝各位的參與。現在您可以斷開線路,祝您週末愉快。